Sonia Kounlavouth

Immunology and Microbiology · Life Sciences

6h-index392citations14works33.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(9), SARS-CoV-2 and COVID-19 Research(5), Cancer Immunotherapy and Biomarkers(4), Mosquito-borne diseases and control(3), RNA Interference and Gene Delivery(3)

Publications14 total

P-100. Durable immune response induced by self-amplifying mRNA (samRNA) SARS-CoV-2 vaccine candidates against variants of concern (VOC) in HIV-negative and people living with HIV (PLWH) populations in South Africa, irrespective of prior SARS-CoV-2 vaccination
Open Forum Infectious Diseases·2025Open Access
A novel HLA Class II presentation prediction algorithm deciphers immunogenic CD4 epitopes specific to KRAS G12C
2024Open Access
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
Nature Medicine·2024· 100 cited
2372. Preliminary evidence of durable immune responses induced by self-amplifying mRNA (samRNA) vaccine candidates against SARS-CoV-2 in vaccine-naive South African population
Open Forum Infectious Diseases·2023· 1 citedOpen Access
2346. Preliminary results of durable immune response induced by a self-amplifying mRNA (samRNA) SARS-CoV-2 vaccine candidate, GRT-R910, in adults previously vaccinated with mRNA or AZD1222 primary series
Open Forum Infectious Diseases·2023Open Access
GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults
Nature Communications·2023· 37 citedOpen Access
Abstract 2267: HLA-DR-restricted CD4 T cell responses to KRAS G12C in healthy donors linked to bacterial mimotope: lessons for KRAS neoantigen vaccines in cancer patients
Cancer Research·2023
1974. Title: A novel low-dose self-amplifying mRNA vaccine (GRT-R910) induces strong and broad boost in cellular and humoral immune response following primary series with a chimpanzee adenovirus SARS-CoV-2 vaccination
Open Forum Infectious Diseases·2022Open Access
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Nature Medicine·2022· 206 citedOpen Access
Abstract 4159: Lower doses of self-amplifying mRNA drive superior neoantigen-specific CD8 T cell responses in cancer patients versus high doses
Cancer Research·2022· 1 cited
960MO Clinical outcomes and immune responses in a phase I/II study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC
Annals of Oncology·2021· 8 cited
Longitudinal Analysis of Memory B and T Cell Responses to Dengue Virus in a 5-Year Prospective Cohort Study in Thailand
Frontiers in Immunology·2019· 17 citedOpen Access
Presentation_1_Longitudinal Analysis of Memory B and T Cell Responses to Dengue Virus in a 5-Year Prospective Cohort Study in Thailand.pdf
Figshare·2019Open Access
Multiplexed FluoroSpot for the Analysis of Dengue Virus– and Zika Virus–Specific and Cross-Reactive Memory B Cells
The Journal of Immunology·2018· 22 citedOpen Access

Frequent Co-authors

Meghan G. Hart(10), Karin Jooss(10), Christine D. Palmer(9), Martina Marrali(7), Amy Rappaport(6), Harshni Venkatraman(6), Jason R. Jaroslavsky(5), Andrew R. Ferguson(5), Ciaran D. Scallan(4), Rita Zhou(4), Alexander I. Spira(4), Melissa L. Johnson(4), Melissa A. Kachura(4), Jason Jaroslavsky(4), Matthew J. Davis(3), Leonid Gitlin(3), Lauren D. Kraemer(3), Desiree Schenk(3), Charmaine N. Nganje(3), Kyounghwa Bae(3)